Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

111.15 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Aug 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 111.15
Bid (Size) 110.96 (3)
Ask (Size) 111.15 (2)
Prev. Close 111.15
Today's Range 111.15 - 111.15
52wk Range 99.14 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.63%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Palantir’s AI Evolution: Strategic Shift Or Marketing Ploy?
Palantir is outgrowing government contract reliance and the AI shift is producing a robust revenue model so far. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
EQNX::TICKER_START (NYSE:ANVS),(NYSE:MRK),(NASDAQ:SNY),(NYSE:JNJ),(NYSE:NVS) EQNX::TICKER_END 
Via FinancialNewsMedia

Performance

YTD
-1.85%
-1.85%
1 Month
-11.63%
-11.63%
3 Month
-14.75%
-14.75%
6 Month
-12.40%
-12.40%
1 Year
+4.77%
+4.77%

More News

Read More
2 Dividend Stocks to Buy and Never Sell
Via The Motley Fool
Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070
From Daiichi Sankyo
Via Business Wire
Behind the Scenes of Merck & Co's Latest Options Trends
Via Benzinga
Decoding Merck & Co's Options Activity: What's the Big Picture?
Via Benzinga
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
From FN Media Group LLC
Via GlobeNewswire
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Via The Motley Fool
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
Via Benzinga
Merck Analysts Slash Their Forecasts After Q2 Results
Via Benzinga
Analyzing Merck & Co In Comparison To Competitors In Pharmaceuticals Industry
Via Benzinga
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
Via Benzinga
Merck's Blockbuster Vaccine Gardasil Sales In China: Analyst Highlights Challenges and Opportunities
Via Benzinga
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
Via Investor's Business Daily
Is It Time to Buy July's Worst-Performing Dow Jones Stocks?
Via The Motley Fool
Topics Stocks
Exposures US Equities
MicroStrategy, Intel And Moderna Are Among Top 12 Large Cap Losers Last Week (July 28-August 3): Are The Others In Your Portfolio?
Via Benzinga
2 Ultra-High-Yield Dividend Stocks to Buy in August and Hold at Least a Decade
Via The Motley Fool
MarketBeat Week in Review – 7/29 - 8/2
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
Via Benzinga
Exposures COVID-19
What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.
Via InvestorPlace
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood's Ark Adds Over $19M Worth Of Moderna Shares After Thursday's 21% Plunge On Guidance Cut
Via Benzinga
Top 3 Health Care Stocks That Are Set To Fly This Quarter
Via Benzinga
IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer
From Daiichi Sankyo
Via Business Wire
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.